Market Positioning | Certara navigates fragmented biosimulation landscape with specialized drug development tools, facing competition from internal pharma capabilities and market consolidation pressures |
Growth Trajectory | Earnings per share projected to grow 21 percent from $0.47 to $0.57, supported by improving biopharma financing and anticipated Tier 1 customer recovery |
Analyst Perspectives | Average price target stands at $14.00, with Overweight ratings reflecting confidence in biosimulation market positioning despite near-term headwinds |
Leadership Evolution | Jon Resnick assumes CEO role bringing biopharma commercial expertise to accelerate product adoption and navigate strategic portfolio optimization |
Metrics to compare | CERT | Sector Sector - Average of metrics from a broad group of related Technology sector companies | Relationship RelationshipCERTPeersSector | |
|---|---|---|---|---|
P/E Ratio | −83.4x | −0.2x | −0.4x | |
PEG Ratio | 0.21 | −0.01 | 0.00 | |
Price / Book | 1.2x | 1.6x | 2.6x | |
Price / LTM Sales | 3.0x | 1.8x | 3.0x | |
Upside (Analyst Target) | −5.6% | 50.8% | 56.0% | |
Fair Value Upside | Unlock | 41.3% | 9.1% | Unlock |
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific. It offers model-informed drug development solutions; biosimulation solutions to predict pharmacokinetics and pharmacodynamics; Simcyp simulator, a mechanistic biosimulation platform for physiologically based pharmacokinetic simulation; Simcyp Discovery for scientists working on pre-investigational new drug and translational stages; Simcyp Biopharmaceutics for formulation scientists; and Simcyp Secondary Intelligence that integrates toxicology with quantitative analysis of large networks of molecular and functional biological changes. It also provides Phoenix WinNonlin, a platform for non-compartmental analysis; Phoenix cloud that offers a secured and validated Certara Amazon Web Services workspace; Phoenix NLME, a population modeling and simulation software; and Pirana Modeling Workbench, which provides modelers with a structure to facilitate the iterative processes. In addition, it offers Chemaxon JChem engines, a chemical search engine; Chemaxon Compound Registration that supports a streamlined lead optimization process workflow; Chemaxon Design Hub, a design and tracking platform; Certara D360 software, a scientific informatics system; and Chemaxon Marvin, a chemical drawing tool. Further, the company provides pinnacle 21, a cloud-based platform for clinical data automation, standardization, and validation; Pinnacle 21 Data Exchange to define data standards and specifications; Metadata Repository that enables study design using controlled and standardized data; CoAuthor software, which creates and writes regulatory submissions and medical publications; and GlobalSubmit, a submissions management software. Certara Inc. was founded in 2008 and is headquartered in Radnor, Pennsylvania.